Who are RGB-14-P's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): quetiapine fumarate vs risperidone, Intramuscular aripiprazole, olanzapine, Quetiapine Immediate Release, quetiapine (Seroquel) XR, Oral Olanzapine, Risperidone, Haloperidol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rgb-14-p.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

RGB-14-P — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

RGB-14-P (RGB-14-P) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Serotonin receptor antagonist. Area: Psychiatry.

phase 3 Serotonin receptor antagonist 5-HT2A receptor Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

RGB-14-P (RGB-14-P) — Gedeon Richter Plc.. RGB-14-P is a small molecule that targets the serotonin receptor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
RGB-14-P TARGET	RGB-14-P	Gedeon Richter Plc.	phase 3	Serotonin receptor antagonist	5-HT2A receptor
quetiapine fumarate vs risperidone	quetiapine fumarate vs risperidone	AstraZeneca	marketed	Atypical antipsychotic	Dopamine D2 receptor, serotonin 5-HT2A receptor
Intramuscular aripiprazole, olanzapine	Intramuscular aripiprazole, olanzapine	Veterans Medical Research Foundation	marketed	Atypical antipsychotic	Dopamine D2 receptor; Serotonin 5-HT2A receptor; Serotonin 5-HT1A receptor
Quetiapine Immediate Release	Quetiapine Immediate Release	AstraZeneca	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
quetiapine (Seroquel) XR	quetiapine (Seroquel) XR	Dr. D McIntosh & Dr. K Kjernisted Clinical Research Inc.	marketed	Atypical antipsychotic	Dopamine D2 receptor, serotonin 5-HT2A receptor
Oral Olanzapine	Oral Olanzapine	Eli Lilly and Company	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
Risperidone, Haloperidol	Risperidone, Haloperidol	Ludwig-Maximilians - University of Munich	marketed	Antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Serotonin receptor antagonist class)

Addpharma Inc. · 2 drugs in this class
Shire · 2 drugs in this class
Gedeon Richter Plc. · 1 drug in this class
Geropharm · 1 drug in this class
H. Lundbeck A/S · 1 drug in this class
Infan Industria Quimica Farmaceutica Nacional · 1 drug in this class
Phytopharm Consulting Brazil · 1 drug in this class
Taisho Pharmaceutical Co., Ltd. · 1 drug in this class
Aclaris Therapeutics, Inc. · 1 drug in this class
Visirna Therapeutics HK Limited · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). RGB-14-P — Competitive Intelligence Brief. https://druglandscape.com/ci/rgb-14-p. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing